Reviewing Opiant Pharmaceuticals Inc. (OPNT)’s and Prana Biotechnology Limited (NASDAQ:PRAN)’s results

As Biotechnology businesses, Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) and Prana Biotechnology Limited (NASDAQ:PRAN), are affected by contrast. This especially applies to their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals Inc. 33.65M 1.73 2.38M -3.91 0.00
Prana Biotechnology Limited N/A 0.00 N/A -0.67 0.00

Demonstrates Opiant Pharmaceuticals Inc. and Prana Biotechnology Limited earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals Inc. -7.07% 0% 0%
Prana Biotechnology Limited 0.00% -37.8% -34.3%

Risk & Volatility

A 1.17 beta indicates that Opiant Pharmaceuticals Inc. is 17.00% more volatile compared to Standard & Poor’s 500. Prana Biotechnology Limited’s 111.00% less volatile than Standard & Poor’s 500 volatility due to the company’s -0.11 beta.

Liquidity

The current Quick Ratio of Opiant Pharmaceuticals Inc. is 7.9 while its Current Ratio is 7.9. Meanwhile, Prana Biotechnology Limited has a Current Ratio of 7.1 while its Quick Ratio is 7.1. Opiant Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Prana Biotechnology Limited.

Insider and Institutional Ownership

Roughly 17.2% of Opiant Pharmaceuticals Inc. shares are owned by institutional investors while 3.5% of Prana Biotechnology Limited are owned by institutional investors. Insiders owned 0.4% of Opiant Pharmaceuticals Inc. shares. Competitively, 18.7% are Prana Biotechnology Limited’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Opiant Pharmaceuticals Inc. 0.69% -8.04% -26.49% 1.14% -47.22% -30.52%
Prana Biotechnology Limited -9.31% -14.69% -22.56% -22.61% -50.97% -51.6%

For the past year Opiant Pharmaceuticals Inc.’s stock price has smaller decline than Prana Biotechnology Limited.

Summary

Opiant Pharmaceuticals Inc. beats Prana Biotechnology Limited on 6 of the 9 factors.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.

Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of AlzheimerÂ’s: and that is in Phase IIa clinical trials for the treatment of HuntingtonÂ’s diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for ParkinsonÂ’s disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.